
Please try another search
Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of original small molecule drugs. The company develops precursor compounds and original new drug product lines for the treatment of human diseases in five therapeutic areas, including cancer, metabolic diseases, autoimmune disorders, central nervous system disorders, and antivirals. It is developing chidamide, a subtype-selective benzamide inhibitor of histone deacetylase (HDAC) primarily targeting subtypes 1, 2, 3 of class I HDAC; chiglitazar, a new-generation insulin sensitizing candidate drug for the treatment of type 2 diabetes mellitus; and chiauranib, an aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor. The company also develops CS23546, a small molecule PD-L1 inhibitor for CS23546 is a small molecule PD-L1 inhibitor; CS32582, a highly selective small molecule allosteric inhibitor of tyrosine kinase 2; CS12192, a highly selective JAK3 kinase inhibitor; and other drugs, such as CS12088 and CS23074. Shenzhen Chipscreen Biosciences Co., Ltd. was founded in 2001 and is headquartered in Shenzhen, China.
Name | Age | Since | Title |
---|---|---|---|
Xian-Ping Lu | 60 | 2001 | Founder, Chairman, GM, CEO & President |
Ou Hai | 45 | 2018 | VP, Deputy GM, Secretary of the Board, Head of Legal & Intellectual Property Department and Director |
Jian-Xun Li | 54 | 2018 | Co-General Manager, Head of Finance & Director |
Jie He | 39 | 2019 | Chairman of the Supervisory Board |
Xia Jin | 47 | 2021 | Employee Supervisor |
Hanpeng Yang | 57 | 2024 | Director |
Weihua Li | 48 | 2023 | Director |
Yanmei Wang | 60 | 2024 | Independent Director |
Shengli Tong | 57 | 2022 | Supervisor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review